With data on adults from two previous articles it was found that the average steady-state plasma concentration of verapamil in subjects on long-term oral therapy of 80 mg every 6 hr (Y) correlated strongly with the area under the curve from zero to infinity (AUC'16 (X) where the area refers to that for a single oral dose of 80 mg (i> = 2.41X, n =-15, r = 0.923, P <0.001). Steady-state concentrations are predictable from the single-dose data, with an average absolute deviation of 11.1%. We gave seven children (7 to 19 yr old) an initial intravenous bolus dose of 0.1 mg /kg, followed by a 20-min constant rate infusion of 0.007 mglkglmin. Twenty-four hours after the bolus dose they were put on oral therapy (40 
specifically, sarcolemmal calcium stores in the myocardium and is remarkably effective in preventing coronary spasm' and in treating patients with hypertrophic cardiomyopathies.
Verapamil kinetics have been studied in dogs and the changes in arterioventricular conduction time, as estimated from the PR interval of the surface ECG, have been correlated with the logarithm of the plasma verapamil concentration. '° The kinetics of the drug were also studied in nor- Half-life mal subjects and patients,1-3, 5-7, 11, 12, 14, 15, 22,23 but kinetics in children have not been reported to date. Koup et al. , 8' 9 Slattery et al. , 17 and Slattery18 have been remarkably successful in predicting the maintenance dose required to attain a desired drug from a single determination of concentration after an initial dose. They have also successfully predicted clearance of chloramphenicol in infants and children from a single serum sample obtained 6 hr after the initial intravenous dose. Indirectly such correlations involve relating Cm of a drug to a single concentration measured after an initial dose.
Recently both Freedman et al. 5 and Shand et al.15 reported that there is a marked reduction in verapamil clearance between the time of the first dose and attainment of steady state. As a result of this, Freedman et al. stated that "kinetic predictions based on single doses will not give reliable estimates for long-term oral dosage. "5 We examined this hypothesis in adults, using the published data of Freedman et al. and Shand et al., and in children, using single-dose intravenous and steady-state oral data we obtained.
Methods
Adults. Freedman et al. reported the plasma verapamil AUC° after a single oral dose (D,) of 80 mg in nine subjects and the AUC°' after long-term oral doses of 80 mg every 6 hr to the same nine subjects. Shand et al. reported Children. Our subjects were seven children (two girls; five boys; 7 to 19 yr old; mean age 12 yr) with documented hypertrophic cardiomyopathy. Five of the seven patients were found at the time of cardiac catheterization to have a resting systolic left ventricular outflow tract gradient greater than 10 mm Hg. All patients were symptomatic as a result of their disease. The symptoms included: marked resting or postexertional dyspnea (all seven patients), chest pain (six patients), and one or more syncopal episodes (four patients).
Routine biochemical investigations revealed normal renal and hepatic function in all patients. No medications were taken in the preceding 48 hr. All studies were performed in the fasting state and all seven patients were given morphine sulfate and diphenhydramine as premedication.
Verapamil was given intravenously to all patients at the time of cardiac catheterization.
Verapamil HC1 was injected as an initial intravenous bolus of 0.1 mg/kg over 2 min, followed by a 20-min continuous infusion of 0.007 mg/kg/min The ECG, systemic arterial, left ventricular, and pulmonary artery pressures were continuously monitored. Blood samples (5 to 7 ml) were drawn before verapamil, just as the infusion ceased (0 time), and at 0.1, 0.25, 0.5, I, 2, 4, 8, 12, 16, 18 , and 22 hr after the infusion. Blood was transferred to heparinized tubes and centrifuged and the plasma was stored at 20° until analyzed. Oral dosage was initiated (either 40 or 80 mg every 6 hr) 24 hr after the bolus dose and a month later a blood sample was taken at 6 hr after a dose at steady state. The latter samples provided the CVn. In one patient (Bo) a single oral dose of 40 mg of verapamil was given 24 hr after the intravenous bolus dose and initiation of the 20-min infusion. For this patient blood was also collected just before oral dosing (0 time) and at 0.25, 0.5, 0.75, 1, 2, 3, and 4 hr after dosing. Verapamil and norverapamil were measured in plasma by a sensitive and specific GLC procedure with a nitrogen-sensitive detector.' 9
Postinfusion verapamil plasma concentrations were computer fitted by the method of least-squares as follows: 
where the Cis correspond to a bolus dose of 0.1 mg/kg of verapamil only and t is now time after the bolus dose (see footnote to Table II) . A large number of correlations were made to find the optimum parameter to predict the verapamil plasma CVns after long-term oral therapy from the intravenous data. In each case the observed CIL'ins were used as the X (abscissa) values and an estimated intravenous concentration, corresponding to the oral dose, was calculated from the fitted parameters (coefficients and exponents) obtained from the single-dose intravenous data and used as the Y (ordinate) values. (The estimated intravenous concentrations used are explained in columns 2 and 3 of, and in the footnotes to, Children. Table I ing the bolus dose of 0.1 mg/kg and constantrate infusion of 0.14 mg/kg (total intravenous dose, 0.24 mg/kg) given over 20 min. Table II gives the results of computer fitting of the data shown in Table Ito our seven children the t1/2 estimated as 0.693/X was shorter than that estimated as 0.693/X1
Adults
( (B) plasma verapamil CV at 3 hr after dosing when both bolus doses and infusions are given intravenously, as in our protocol, (C) plasma verapamil CV at 12 hr after a single intravenous bolus dose, (D) plasma verapamil CV at 12 hr after a bolus dose and an infusion, as in our protocol, (E) as in function A except only terminal intravenous data are used (Table V) and t = 4 hr rather than 3 hr, and (F) as in function C except only terminal intravenous data are used and t = 9 hr rather than 12 hr. In all the correlations the predicted intravenous concentrations correspond to the oral doses (as a result of the use of the D,,/Div ratios shown in Table IV ). Confirmation of these correlations should not be attempted by experimental means since the oral doses are too high to be given intravenously, but a lower dose could be given and the dose ratio Dpo/Div could be used to correct the measured values. It should be noted that as the r2 and r values decrease, the mean absolute deviations in a predicted CVn increase considerably (Table VI) . t MRT = mean residence time = /(C,A)A(C,/X,) (see Table ll Fig. 1 involves only oral dosing, hence the first-pass effect is involved in both the single-dose and steady-state results. However, some or all of the factors involved in the first pass, namely bioavailability (or extraction ratio), hepatic clearance, and possibly effective liver blood flow, must change considerably to account for the slope of 2.41. Since the individual subject verapamil plasma concentrations after the single or first doses and those obtained at steady state
were not available in the articles of Freedman et al. and Shand et al., single-point correlations, as described by others,9' 9' 17' 18 could not be studied, but such studies may be fruitful.
Children. Since there is extensive first-pass metabolism of verapamil the challenge to predict CZ," for long-term oral therapy from single-dose intravenous data was considerable. When the observed verapamil plasma concen- (Table I) were correlated with the CV's after 1 mo of oral therapy (Table IV) , the best correlation was obtained for t = 4 hr and for that correlation (r3 = 0.751). The latter is lower than any r3 value in Table VI Table VII , concerning length of the blood sampling time are related to other observations we have made concerning data in the literature. The 6-hr sampling period of Dominic et al.' was not long enough to reach the true log-linear phase since they reported an average t1/2 of 1.8 hr, which is considerably shorter than that reported by others.2, 3, 5, 6. 11, 15. 22 The mean elimination t1/2 of 9.17 hr that we obtained in children by Prediction of verapamil steady-state levels 179 polyexponential fitting was longer than the mean t1/2 of 6.40 hr that we obtained by use of only terminal concentrations; even the latter is longer than the t1/2 in adults reported by others.1-3, 5, 6, 11, 15, 22 The mean clearance of 0.500 //min we found in the seven children is also lower than the mean clearances in the range 0.576 to 1.57 //min reported for adults by others.1, 3, 5, 6, 11, 22 Thus, it appears that both the clearance and elimination rate constant of verapamil may be smaller in children than in adults. This is so even when it is normalized to body weight; the mean clearance was 11.9 (7.32 omitting patient T) ml/min/kg in the seven (or six) children. In general, evaluation of our child data and the adult data of Eichbaum Table IV ) and the X shown in columns 2 and 3 above.
*The mean absolute (sign ignored) deviation of the predicted from the observed verapamil plasma concentration. §P < 0.001. lip < 0.01.
11In these correlations only terminal postinfusion data were used (see Tables I and V) . Table II suggests that blood was not sampled long enough to observe the terminal loglinear phase.
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